About the journal
Immuno-Oncology and Technology is an open-access journal published by Elsevier in United Kingdom, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 3,490 USD. Declared review time at DOAJ: 29 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Elsevier
- ISSN
- 2590-0188
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 3,490 USD
- Articles in DOAJ
- 159
- Declared review time
- 29 weeks
- Declared peer-review model
- peer_review
Index listings
- DOAJ · 2021-10-19
- Indexing
- DOAJ
- APC
- 3,490 USD
- Declared review time (DOAJ)
- 29 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
159
Most recent article
2 months ago
Average review time (journal-declared via DOAJ)
29weeks
Works in OpenAlex
1233
Last recorded publication year
2026
h-index
20
i10-index
48
From OpenAlex open data (CC0).
Editorial & policy12
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2021-10-19
- Declared plagiarism screening
- Not declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPMCPortico
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 9%
- ORCID iDs in current deposits
- 7%
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity3
- Alternate titles
- Immuno-oncology and technologyIOTECH
- Source type
- journal
- NLM unique ID (PubMed)
- 9918281581106676
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
Show all subjects (50)
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Diverse Scientific and Economic Studies
- Diverse Scientific and Economic Studies
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Colorectal Cancer Treatments and Studies
- Cancer Research and Treatments
- Immune cells in cancer
- Immune cells in cancer
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Peptidase Inhibition and Analysis
- Immune Cell Function and Interaction
- Immune Cell Function and Interaction
- Melanoma and MAPK Pathways
- Melanoma and MAPK Pathways
- Cutaneous Melanoma Detection and Management
- Virus-based gene therapy research
- Human auditory perception and evaluation
- Cutaneous Melanoma Detection and Management
- Human auditory perception and evaluation
- Virus-based gene therapy research
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Lung Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Nanoplatforms for cancer theranostics
- Educational Robotics and Engineering
- Nanoplatforms for cancer theranostics
- Educational Robotics and Engineering
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Ferroelectric and Negative Capacitance Devices
- Radiopharmaceutical Chemistry and Applications
- Ferroelectric and Negative Capacitance Devices
- Radiopharmaceutical Chemistry and Applications
Keywords (DOAJ)
- oncology
- immunotherapy
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ